In addition to TTP and OGS today ...
NEW HAVEN, Conn., Feb. 25 /PRNewswire/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN - news) today announced that it intends to offer, subject to market and other conditions, approximately $120 million of Convertible Subordinated Notes due 2007 ($150 million if an option for an additional $30 million is exercised in full)
ViroPharma Incorporated today announced that it has increased its previously announced private placement of Convertible Subordinated Notes due 2007 to $150 million (up from $100 million) and has priced the offering. The offering, which was made through initial purchasers to qualified institutional buyers under Rule 144 A of the Securities Act of 1933 and to a limited number of institutional accredited investors, is expected to close on March 1, 2000. The notes are convertible into shares of ViroPharma common stock at a price of $109.15 per share, subject to certain adjustments. ViroPharma also has granted the initial purchasers of the notes an option to purchase up to an additional $30 million in principal amount of the notes. The notes will bear interest at a rate of 6 percent per annum, have a 7-year term, and can be redeemed by ViroPharma, at certain premiums over the principal amount, at any time after March 6, 2003.
UNIONDALE, N.Y., Feb. 25 /PRNewswire/ -- OSI Pharmaceuticals, Inc. (Nasdaq: OSIP - news) announced today that it has entered into definitive purchase agreements to raise $56 million in gross proceeds through a private sale of 3.325 million newly-issued shares of its common stock to a select group of institutional investors.
cash is flowing...
nig |
